Stephens initiated coverage of Fennec (FENC) with an Overweight rating and $15 price target The firm is adding to its Biotechnology research coverage with a focus on targeted protein degradation, or TPD, technology and commercial and clinical-stage rare disease-focused companies. Fennec is a specialty pharmaceutical company on the market for the treatment of ototoxicity in pediatric patients with PEDMARK receiving chemotherapy and the firm anticipates it to have meaningful penetration into adolescent and young adult, or AYA, market in 2025, the analyst tells investors.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FENC:
- Fennec Pharmaceuticals Reports Strong Q3 Results
- Fennec Pharmaceuticals Reports Q3 2024 Financial Results
- Fennec price target lowered to $15 from $22 at Maxim
- Fennec reports Q3 EPS (21c), consensus (9c)
- Fennec Pharmaceuticals Strengthens Leadership Team for Growth
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
